A number of research firms have recently commented on Synageva BioPharma Corp (NASDAQ:GEVA). Analysts at Morgan Stanley reiterated an “overweight” rating on shares of Synageva BioPharma Corp in a research note on Tuesday. They now have a $118.00 price target on the stock. Synageva BioPharma Corp (NASDAQ:GEVA) shares after opening at $72.80 moved to $77.62 on last trade day and at the end of the day closed at $76.64. Company price to sales ratio in past twelve months was calculated as 188.40 and price to cash ratio as 6.18. Synageva BioPharma Corp (NASDAQ:GEVA) showed a negative weekly performance of -7.63%.
Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, today announced the presentation of positive results from the Phase II clinical trial of Puma’s investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL) in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, California. Puma Biotechnology Inc. (NYSE:PBYI) shares fell -18.30% in last trading session and ended the day on $86.94. PBYI return on equity ratio is recorded as -54.10% and its return on assets is -44.80%. Puma Biotechnology Inc. (NYSE:PBYI) yearly performance is 182.27%.
One stock that might be an intriguing choice for investors right now is Intrexon Corporation (NYSE:XON). This is because this security in the medical services space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. Intrexon Corp (NYSE:XON) shares moved down -4.43% in last trading session and was closed at $22.43, while trading in range of $20.99 – $23.14. Intrexon Corp (NYSE:XON) year to date (YTD) performance is -5.76%.
Irish specialty pharmaceutical company Mallinckrodt Plc yesterday struck a deal to buy US drugmaker Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) for $5.6 billion to acquire its multiple sclerosis drug Acthar Gel, in a bid to expand its own portfolio. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) weekly performance is 24.10%. On last trading day company shares ended up $80.58. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) distance from 50-day simple moving average (SMA50) is 20.96%. Analysts mean target price for the company is $88.00.